On July 2, Thermo Fisher Scientific rose 3.01% in regular trading, trading at 528.105 USD/share, with turnover of $298 million.

On the news front, Arcturus Therapeutics announced a strategic collaboration with Thermo Fisher Scientific, granting Thermo Fisher exclusive commercial manufacturing rights for its cystic fibrosis investigational therapy ARCT-032. Under the agreement, Thermo Fisher will leverage its Accelerator Drug Development solutions, covering manufacturing and clinical research capabilities, to support the therapy from phase 2 development through potential commercialization. Should the phase 2 program yield positive results, Arcturus expects to carry out the phase 3 program through Thermo Fisher's PPD clinical research business. No financial terms were disclosed.

The collaboration aims to establish a robust manufacturing foundation for ARCT-032's future global supply, ensuring reliable and efficient commercialization. This deal further reinforces Thermo Fisher's expanding role in end-to-end pharmaceutical services, building on recent strategic moves including the $8.88 billion Clario acquisition completed in March and the opening of a flagship bioprocess design center in April.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)